Business
Strategy/Company/Ops Update
Strategy/Company/Ops Update.
About this update from Tekcapital Plc
[{"type":"text","content":"\n \nRNS Number : 4089C Tekcapital plc 10 February 2020 \n\n \n \nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service (\"RIS\"), this inside information is now considered to be in the public domain.\n \n10 February 2020\n \nTekcapital plc\n (\"Tekcapital\" or the \"Company\")\nPortfolio Company Update\n Belluscura plc files new patent application for devices and systems for treating people \nsuffering from acute respiratory distress caused by the Coronavirus\n \nTekcapital plc, (AIM: TEK) the UK intellectual property investment group focused on creating marketplace value from investing in university technology, announces that its portfolio company Belluscura plc has recently filed a patent application on an oxygen enrichment device and system for treating acute respiratory distress (ARDS), including ARDS caused by Coronavirus.\nBelluscura plc, in conjunction with its exclusive research partner Separation Design Group, announced the filing of a patent application covering novel integrated portable extracorporeal oxygenation and carbon dioxide removal systems for treating patients suffering from ARDS.\nThe latest patent application covers devices and systems for treating people suffering from ARDS including patients suffering from the coronavirus. The primary cause of death from respiratory viruses like the coronavirus and influenza, are the result of the fluids accumulating inside the alveoli (the tiny air sacs of the lungs) which ultimately leads to the failure of the transfer of oxygen to and carbon dioxide out of the blood. The current primary treatment for ARDS is oxygen therapy along with ventilator support.\nIn cases where oxygen therapy and ventilator support are not effective, extracorporeal membrane oxygenation (ECMO), which circulates a patient's blood through an oxygenation membrane, has been used to remove carbon dioxide from and diffuse oxygen into a patient's blood while giving a patient's lungs a chance to recover. Belluscura and Separation Design are designing and developing next generation, cost-effective, portable ECMO technology to treat ARDS ...